All News
2022 Memorium
Sadly, too many of our rheumatology colleagues passed on in 2022. Here is an (incomplete) list of notable brethren, mentors, do-gooders and great rheumatologists:
Read Article
2022 Rheumatology Year in Review (1-6-2023)
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
Read Article
2022 Rheumatology Year in Review
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Read Article
Differential Dx of hyperferritinemia (≥500 μg/) in critically ill ICU pts includes: sepsis, liver disease/failure, hematological malignancy, HLH. Single center study of 2583 patients https://t.co/F5Dz2qpmAy https://t.co/ZWnxHGoQR1
Links:
Dr. John Cush RheumNow ( View Tweet)
ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis
The guideline is based on a systemic review and network meta-analysis conducted by the ACP Center for Evidence Reviews at the Portland Veteran Affairs Research Foundation.
https://t.co/Tx6PnpCEOp https://t.co/AVsnC1yubI
Links:
Dr. John Cush RheumNow ( View Tweet)
Weekly (Ozempic) semaglutide SC was given for obesity, 3-6 mos to 408 pts with BMI> 27. Wt loss was 5.9% (6.7 kg) @3 mos & 10.9% (12.3 kg) @6 mos. 55%) had >10% & 8% had > 20% wt loss. NIDDM pts had less wt loss vs non-DM pts. https://t.co/LXpP5OR5GA https://t.co/ioPA9WpJu3
Links:
Dr. John Cush RheumNow ( View Tweet)
520 RA pts were screened with FibroScan (liver fibrosis)- F3 or F4 liver fibrosis seen 13.3% of controls vs 12.7% arthritis pts. MTX was not significantly correlated w/ higher FS scores. Liver stiffness was correlated w/ BMI, waist, male , age. https://t.co/nINWp8vbUu
Links:
Dr. John Cush RheumNow ( View Tweet)
Open Access
Risk Factors for Dementia in Patients With Incident Rheumatoid Arthritis: A Population-Based Cohort Study
📰 https://t.co/reGuRVPQSG
#dementia #rheumatoidarthritis https://t.co/0K7URVTkYO
The Journal of Rheumatology jrheum ( View Tweet)
RHEUMATOLOGISTS: have you ever ordered a Fibroscan in patients taking Methotrexate?
Dr. John Cush RheumNow ( View Tweet)
Dr. Kristi Kuhn & Univ of Colorado researchers have linked RA risk with the gut bacterium Subdoligranulum didolesgii. This could be pathogenically important and supports their "Mucosal origins hypothesis" to RA risk https://t.co/EMfNzWSPBK https://t.co/dp7p6vMI4W https://t.co/E1CBUPy2Wp
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Update from ACR22
https://t.co/oqINHvpGLG https://t.co/si99jdDkSA
Links:
Dr. John Cush RheumNow ( View Tweet)
In GCA, Hospital Admission Is Bad News
1/3 of patients admitted w/ GCA were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study.
https://t.co/zaWZn7F9sl https://t.co/OfuyZxNbaa
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us for RheumNow Live this March 18-19 in Dallas, TX! We're not like other meetings--we're answering the questions you want answered.
RNL is a meeting to engage your mind and change your practice. Join us in-person or virtually!
https://t.co/bMphD12Bie https://t.co/Hx0uHAIUWd
Links:
Dr. John Cush RheumNow ( View Tweet)
ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis
The guideline is based on a systemic review and network meta-analysis conducted by the ACP Center for Evidence Reviews at the Portland Veteran Affairs Research Foundation.
https://t.co/Pbsjuh1Bto https://t.co/IwcH04LS4n
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 Match - Strong Appeal of Adult Rheumatology, Less So in Pediatric Rheumatology
The ACR is pleased to announce another successful recruitment season and welcomes this impressive pool of applicants to the field of rheumatology.
https://t.co/XEQCq5Pnnt https://t.co/quvxT9njI4
Links:
Dr. John Cush RheumNow ( View Tweet)
Extreme Global Costs of Physical Inactivity
A global, population-based study shows that physical inactivity is not only an important modifiable risk factor for NCDs and mental health conditions, it also imparts a considerable health and economic burden.
https… https://t.co/eZEW6LGpiL
Dr. John Cush RheumNow ( View Tweet)
Should Kids w/ MIS-C get the COVID vaccine? Yes - study of 385 pt > 5 yrs w/ Hx of multisystem inflammatory syndrome showed no serious adverse events after COVID-19 vaccination. The safety profile of COVID-19 vax is same as gen population https://t.co/dr2QBQsMhE? https://t.co/WbsUuYEsez
Links:
Dr. John Cush RheumNow ( View Tweet)
The Dartmouth Hitchcock Medical Center (DHMC) is searching for a new Chief of the Section of Rheumatology - one who is dynamic, experienced, future-oriented academic Rheumatologist https://t.co/TD6gjWAzZu https://t.co/p4NSe6VtKD
Links:
Dr. John Cush RheumNow ( View Tweet)
The Daily Mail in the UK features a long review of Hx of #Gout (Disease of Kings) & being on the rise in the UK - features a video interview with Professor Philip Conahan (one of our speakers at RheumNow Live 2023!) https://t.co/dNC71DwXTf https://t.co/ZtmQgx5aHc https://t.co/2D3HE0GFO5
Dr. John Cush RheumNow ( View Tweet)
Weekly (Ozempic) semaglutide SC was given for obesity, 3-6 mos to 408 pts with BMI> 27. Wt loss was 5.9% (6.7 kg) @3 mos & 10.9% (12.3 kg) @6 mos. 55%) had >10% & 8% had > 20% wt loss. NIDDM pts had less wt loss vs non-DM pts. https://t.co/05O6hlNm2G https://t.co/ppxjLOE03B
Links:
Dr. John Cush RheumNow ( View Tweet)
